Full Breakdown
FDA Rejects Replimune's Melanoma Therapy RP1 Amid Leadership Turmoil
5/15/2026, 10:06:45 PM
The Decision and Its Immediate Impact
On 23 April 2025 the FDA denied accelerated approval for RP1, an oncolytic herpesvirus combined with Opdivo, citing methodological flaws, the absence of a control arm, and insufficient evidence that the observed tumor responses were attributable to RP1 rather than Opdivo.
Background: Melanoma, RP1, and Accelerated Approval
Melanoma accounts for roughly 112 000 new U.S. cases and 8 500 projected deaths in 2025. RP1 was granted breakthrough-therapy designation after early-stage data and sought accelerated approval based on a single-arm phase 1/2 trial of 140 patients that reported a 33.6 % overall response rate. Single-arm designs have previously supported approvals, most notably Merck’s Keytruda for melanoma.
Key Figures and Stakeholders
- Marty Makary – FDA commissioner (resigned 12 May 2025)
- Kyle Diamantas – Deputy commissioner for food, acting commissioner
- Trisha Wise-Draper – Dermatologist, University of Cincinnati
- Eric Whitman – Medical director, Atlantic Health System oncology service
- Paul Kim – Former FDA staffer, Senate aide to Sen. Edward Kennedy
- Aaron Kesselheim – Harvard Medical School professor, drug-policy expert
- Sushil Patel – CEO, Replimune
- President Donald Trump – Commented on Makary’s tenure
- Robert F. Kennedy Jr. – HHS secretary, supported Makary
- John Crowley – President, Biotechnology Innovation Organization (BIO)
Timeline of Events
- Nov 2024 – Replimune submits RP1 for approval.
- Jul 2025 – FDA issues first complete-response letter warning about trial design.
- Apr 23 2025 – FDA issues second denial letter rejecting RP1.
- May 5 2025 – Makary accuses Replimune of “corporate spin” in a CNBC interview.
- May 12 2025 – Makary resigns; Diamantas becomes acting commissioner.
- May 2025 – Replimune announces layoffs affecting >50 % of staff.
Data & Statistics
- Trial enrolled 140 patients; 33.6 % achieved tumor shrinkage or disappearance.
- Approximately 2 000–2 500 patients could have benefited, according to oncologists.
- Replimune’s stock rose 7 % after Makary’s resignation.
- Roughly 3 500 FDA employees have left since March 2025; 4 000 were dismissed early in the Trump administration.
Why It Matters
The denial removes a potentially life-extending option for advanced melanoma patients and fuels uncertainty for biotech firms relying on accelerated-approval pathways. The episode also highlights perceived inconsistency in FDA decision-making during a period of rapid leadership turnover, raising concerns about investor confidence and U.S. competitiveness in biomedical innovation.
Official Statements & Responses
- FDA: Rejected RP1 because the data did not convincingly isolate RP1’s effect and the single-arm design failed to meet evidentiary standards.
- Makary: Defended the decision as science-based and labeled Replimune’s advocacy “corporate spin.”
- President Trump: Praised Makary’s work but noted “difficulty” in his role.
- HHS Secretary Kennedy: Backed Makary, mistakenly asserting chemotherapy was part of the trial.
- John Crowley (BIO): Called for “strong, stable and science-driven leadership” at the FDA.
- Aaron Kesselheim: Warned the agency may be lowering the evidence threshold for drug approval.
Criticism & Opposition
Oncologists Wise-Draper and Whitman described the denial as “devastating” and a possible loss of life for thousands. Paul Kim argued that the agency’s rationale was opaque, suggesting political influence. A Wall Street Journal editorial warned the ruling could chill future drug development.
On-the-Ground Reports
Physicians reported several patients achieving complete remission after RP1, and families expressed disappointment that the therapy will not become available despite promising early results.
Conflicting Reports & Gaps
Replimune claimed a control arm was ethically impossible, while FDA officials insisted a comparator was required. The agency had previously approved single-arm melanoma drugs, creating a discrepancy not resolved in public statements.
Verbatim Quotes
- “It was devastating news,” — Trisha Wise-Draper, dermatologist, University of Cincinnati
- “This is life or death for maybe 2,000 patients,” — Eric Whitman, medical director, Atlantic Health System oncology service
- “I don't work for Replimune. I work for the American people,” — Marty Makary, FDA commissioner (CNBC, 5 May 2025)
- “All the norms have been thrown out the window, so we don't know what underlines an agency decision,” — Paul Kim, former FDA staffer, Senate aide
- “A treatment desperately needed by patients will not be available. Not because the medicine failed. Because the system did,” — Sushil Patel, CEO, Replimune
- “The FDA is sending signals that it wants to even further reduce the evidence needed to support drug approval,” — Aaron Kesselheim, Harvard Medical School professor
What’s Next
Kyle Diamantas now leads the FDA on an interim basis while a permanent commissioner is selected. Replimune plans to advance RP2, a candidate for metastatic uveal melanoma and hepatocellular carcinoma, and to seek alternative pathways for RP1. Industry observers anticipate a review of accelerated-approval and one-trial policies under the incoming leadership.
